Literature DB >> 31586192

The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community.

Takashi Komori1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31586192      PMCID： PMC6917395          DOI： 10.1093/neuonc/noz186

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Authors:  Gerald F Reis; Melike Pekmezci; Helen M Hansen; Terri Rice; Roxanne E Marshall; Annette M Molinaro; Joanna J Phillips; Hannes Vogel; John K Wiencke; Margaret R Wrensch; Kyle M Walsh; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2015-05       Impact factor: 3.685

2.  cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.

Authors:  David N Louis; David W Ellison; Daniel J Brat; Kenneth Aldape; David Capper; Cynthia Hawkins; Werner Paulus; Arie Perry; Guido Reifenberger; Dominique Figarella-Branger; Andreas von Deimling; Pieter Wesseling
Journal:  Brain Pathol       Date:  2019-05-22       Impact factor: 6.508

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Authors:  Mitsuaki Shirahata; Takahiro Ono; Damian Stichel; Daniel Schrimpf; David E Reuss; Felix Sahm; Christian Koelsche; Annika Wefers; Annekathrin Reinhardt; Kristin Huang; Philipp Sievers; Hiroaki Shimizu; Hiroshi Nanjo; Yusuke Kobayashi; Yohei Miyake; Tomonari Suzuki; Jun-Ichi Adachi; Kazuhiko Mishima; Atsushi Sasaki; Ryo Nishikawa; Melanie Bewerunge-Hudler; Marina Ryzhova; Oksana Absalyamova; Andrey Golanov; Peter Sinn; Michael Platten; Christine Jungk; Frank Winkler; Antje Wick; Daniel Hänggi; Andreas Unterberg; Stefan M Pfister; David T W Jones; Martin van den Bent; Monika Hegi; Pim French; Brigitta G Baumert; Roger Stupp; Thierry Gorlia; Michael Weller; David Capper; Andrey Korshunov; Christel Herold-Mende; Wolfgang Wick; David N Louis; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2018-04-23       Impact factor: 17.088

5.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.

Authors:  David E Reuss; Yasin Mamatjan; Daniel Schrimpf; David Capper; Volker Hovestadt; Annekathrin Kratz; Felix Sahm; Christian Koelsche; Andrey Korshunov; Adriana Olar; Christian Hartmann; Jaap C Reijneveld; Pieter Wesseling; Andreas Unterberg; Michael Platten; Wolfgang Wick; Christel Herold-Mende; Kenneth Aldape; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-12       Impact factor: 17.088

6.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.

Authors:  Adriana Olar; Khalida M Wani; Kristin D Alfaro-Munoz; Lindsey E Heathcock; Hinke F van Thuijl; Mark R Gilbert; Terri S Armstrong; Erik P Sulman; Daniel P Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2015-02-21       Impact factor: 17.088

7.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.

Authors:  Kosuke Aoki; Hideo Nakamura; Hiromichi Suzuki; Keitaro Matsuo; Keisuke Kataoka; Teppei Shimamura; Kazuya Motomura; Fumiharu Ohka; Satoshi Shiina; Takashi Yamamoto; Yasunobu Nagata; Tetsuichi Yoshizato; Masahiro Mizoguchi; Tatsuya Abe; Yasutomo Momii; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Masashi Sanada; Hironori Yajima; Naoya Morita; Ichiro Takeuchi; Satoru Miyano; Toshihiko Wakabayashi; Seishi Ogawa; Atsushi Natsume
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Authors:  Patrick J Cimino; Michael Zager; Lisa McFerrin; Hans-Georg Wirsching; Hamid Bolouri; Bettina Hentschel; Andreas von Deimling; David Jones; Guido Reifenberger; Michael Weller; Eric C Holland
Journal:  Acta Neuropathol Commun       Date:  2017-05-22       Impact factor: 7.801

10.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Authors:  Romain Appay; Caroline Dehais; Claude-Alain Maurage; Agusti Alentorn; Catherine Carpentier; Carole Colin; François Ducray; Fabienne Escande; Ahmed Idbaih; Aurélie Kamoun; Yannick Marie; Karima Mokhtari; Emeline Tabouret; Nesrine Trabelsi; Emmanuelle Uro-Coste; Jean-Yves Delattre; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 13.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.